Andreas Argyrides
Stock Analyst at Oppenheimer
(2.31)
# 2,577
Out of 4,905 analysts
110
Total ratings
51.69%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALA KALA BIO | Assumes: Outperform | $15 | $5.74 | +161.32% | 1 | Jun 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $35.20 | +73.30% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $4.20 | +66.67% | 5 | Jun 2, 2025 | |
| ABEO Abeona Therapeutics | Assumes: Outperform | $19 | $6.59 | +188.32% | 1 | Jun 2, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $60 → $34 | $9.02 | +276.94% | 1 | Jun 2, 2025 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $3 | $0.86 | +247.22% | 2 | May 29, 2025 | |
| LQDA Liquidia | Downgrades: Underperform | $13 | $14.54 | -10.59% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.42 | +862.46% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $13.50 | +566.67% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $2.26 | +298.23% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $13.75 | +9.09% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $169.90 | +6.53% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.04 | +217.03% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $3.21 | +709.97% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $53.09 | +95.89% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.41 | +1,122.49% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.70 | +429.41% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $17.92 | +6.03% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $17.50 | +65.71% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.16 | +157.35% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $14.08 | +1,491.47% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $21.59 | +164.07% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.10 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.96 | +626.14% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.76 | +165.96% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.51 | +1,860.02% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $57.29 | +22.19% | 6 | Aug 1, 2023 |
KALA BIO
Jun 2, 2025
Assumes: Outperform
Price Target: $15
Current: $5.74
Upside: +161.32%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $35.20
Upside: +73.30%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.20
Upside: +66.67%
Abeona Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $19
Current: $6.59
Upside: +188.32%
Dyne Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $60 → $34
Current: $9.02
Upside: +276.94%
InflaRx
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.86
Upside: +247.22%
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $14.54
Upside: -10.59%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.42
Upside: +862.46%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $13.50
Upside: +566.67%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.26
Upside: +298.23%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.75
Upside: +9.09%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $169.90
Upside: +6.53%
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $11.04
Upside: +217.03%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.21
Upside: +709.97%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $53.09
Upside: +95.89%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.41
Upside: +1,122.49%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.70
Upside: +429.41%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $17.92
Upside: +6.03%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $17.50
Upside: +65.71%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.16
Upside: +157.35%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $14.08
Upside: +1,491.47%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $21.59
Upside: +164.07%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.10
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.96
Upside: +626.14%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $3.76
Upside: +165.96%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.51
Upside: +1,860.02%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $57.29
Upside: +22.19%